XTX Topco Ltd Purchases Shares of 67,201 Trevi Therapeutics, Inc. (NASDAQ:TRVI)

XTX Topco Ltd acquired a new position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 67,201 shares of the company's stock, valued at approximately $277,000. XTX Topco Ltd owned approximately 0.09% of Trevi Therapeutics at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Summit Investment Advisors Inc. raised its holdings in shares of Trevi Therapeutics by 84.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock valued at $26,000 after buying an additional 2,894 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Trevi Therapeutics during the fourth quarter worth approximately $49,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Trevi Therapeutics in the 4th quarter worth approximately $67,000. Invesco Ltd. lifted its stake in Trevi Therapeutics by 21.2% in the fourth quarter. Invesco Ltd. now owns 23,621 shares of the company's stock worth $97,000 after purchasing an additional 4,133 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Trevi Therapeutics by 14.5% during the fourth quarter. SG Americas Securities LLC now owns 26,792 shares of the company's stock valued at $110,000 after purchasing an additional 3,387 shares during the period. 95.76% of the stock is currently owned by institutional investors.

Trevi Therapeutics Stock Up 1.2 %

Shares of Trevi Therapeutics stock traded up $0.09 during trading hours on Thursday, reaching $7.00. 891,710 shares of the stock traded hands, compared to its average volume of 1,135,809. The company has a 50 day moving average price of $5.83 and a 200 day moving average price of $4.35. Trevi Therapeutics, Inc. has a one year low of $2.30 and a one year high of $7.39. The firm has a market capitalization of $676.29 million, a price-to-earnings ratio of -15.96 and a beta of 0.41.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.01. Sell-side analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Analysts Set New Price Targets

TRVI has been the subject of a number of analyst reports. Raymond James upgraded shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their target price for the stock from $9.00 to $29.00 in a report on Monday, March 10th. HC Wainwright reiterated a "buy" rating and issued a $12.50 target price on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. D. Boral Capital reiterated a "buy" rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Needham & Company LLC restated a "buy" rating and set a $24.00 target price on shares of Trevi Therapeutics in a research note on Tuesday, April 8th. Finally, Oppenheimer raised their price target on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. Seven research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $17.56.

Insider Transactions at Trevi Therapeutics

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the sale, the insider now owns 76,900 shares of the company's stock, valued at approximately $519,075. The trade was a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Jennifer L. Good sold 5,263 shares of the firm's stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the transaction, the chief executive officer now directly owns 213,313 shares in the company, valued at $1,403,599.54. This trade represents a 2.41 % decrease in their position. The disclosure for this sale can be found here. 24.37% of the stock is currently owned by company insiders.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.